Feasibility, Safety, and Preliminary Clinical Efficacy of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study
This study aims to assess the feasibility, safety, acceptability, and preliminary efficacy trends of a Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) intervention for adolescent depression through a pilot clinical trial. The findings will inform the design and optimization of subsequent formal randomized controlled trials, providing essential evidence for their execution.
Conditions studied
Depression - Major Depressive Disorder
About this study
This study aims to assess the feasibility, safety, acceptability, and preliminary efficacy trends of a Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) intervention for adolescent depression through a pilot clinical trial. The findings will inform the design and optimization of subsequent formal randomized controlled trials, providing essential evidence for their execution.
Interventions
- Device: Experimental target rTMS treatment — Participants will undergo MRI-guided identification of the voxel in the left dorsolateral prefrontal cortex (DLPFC) that is most negatively correlated with the functional connectivity of the subgenual anterior cingulate cortex (sgACC) as the stimulation site.
- Device: Conventional target rTMS treatment — participants will receive MRI-guided stimulation at the left DLPFC location.
- Device: Sham stimulation treatment — Participants will receive a sham stimulation treatment designed to simulate the rTMS procedure without generating an effective magnetic field output.
Primary outcomes
- Recruitment Feasibility (Number of Participants Enrolled) (2 years)
- Intervention adherence (number of participants who completed the full 20 treatment sessions) (Throughout the entire course of treatment (up to 1 month))
- Retention Rate (Number of Participants Remaining at 6-Month Follow-up) (Throughout the entire course of treatment (up to 1 month) and follow-up (up to 6 months))
- Response rate and remission rate of depressive symptoms (Baseline, throughout the entire course of treatment (up to 1 month) and follow-up (up to 6 months))
- Incidence of Adverse Events and Serious Adverse Events (Throughout the entire course of treatment (up to 1 month) and follow-up (up to 6 months))
Eligibility information
Study locations
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-17.